Goldman Sachs raises its price targe to $567 on Neutral-rated Intuitive Surgical ISRG on higher EPS estimates.
Goldman Sachs says, "We maintain our Neutral rating, as we think the stock reflects an appropriately bullish outlook, making the risk/reward balanced. We raise our sales numbers to reflect greater penetration in new surgical categories, but this is partially offset by lower margins (the company indicated no intention to pass the Healthcare Reform Medical Device tax onto customers, which we had previously forecast)."
ISRG closed at $516.86 a share yesterday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in